Evidence map›Paper›PMID 19729043›Full record

ArticleRegulatory peptides2009

A transcriptionally permissive epigenetic landscape at the vasoactive intestinal peptide receptor-1 promoter suggests a euchromatin nuclear position in murine CD4 T cells.

K D Benton, R J Hermann, E E Vomhof-DeKrey, J S Haring, T Van der Steen, J Smith, S Dovat, G P Dorsam

Abstract read
In one paragraph

Article in Regulatory peptides, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Vasoactive intestinal peptide signaling axis in human leukemia.World journal of biological chemistry · 2011
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

K D BentonDepartment of Chemistry and Molecular Biology, North Dakota State University, Fargo, ND 58108, USA.
R J Hermann
E E Vomhof-DeKrey
J S Haring
T Van der Steen
J Smith
S Dovat
G P Dorsam
North Dakota State University · USUniversity of Wisconsin–Madison · US

Funding

TARGETING AND DELIVERYP20RR015566 · NCRR · NORTH DAKOTA STATE UNIVERSITY · PI SIBI, MUKUND P. · 2001 to 2011
$19.0M
HETEROCHROMATIN RECRUITMENT OF THE VPAC1 LOCUS BY IKAROSK01DK064828 · NIDDK · NORTH DAKOTA STATE UNIVERSITY · PI DORSAM, GLENN PAUL · 2004 to 2010
$593k
NCRR NIH HHS 2P20RR015566NCRR NIH HHS P20RR016741NIDDK NIH HHS 1KO1DK064828NIDDK NIH HHS K01 DK064828
6 · The paper itself

Abstract

T cells express receptors for neuropeptides that mediate immunological activities. Vasoactive intestinal peptide receptor-1 (VPAC1), the prototypical group II G protein coupled receptor, binds two neuropeptides with high-affinity, called vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. During T cell signaling, VPAC1 mRNA expression levels are significantly downregulated through a Src kinase dependent mechanism, thus altering the sensitivity for these neuropeptides during an immune reaction. Presently, it is unknown whether the mechanism that regulates VPAC1 during T cell signaling involves epigenetic changes. Therefore, we hypothesized that the epigenetic landscape consisting of diacetylation at H3K9/14 and trimethylation at H3K4, two transcriptionally permissive histone modifications, would parallel VPAC1 expression showing high enrichment in untreated T cells, but lower enrichment in alpha-CD3 treated T cells. To this end, quantitative chromatin immunoprecipitation (ChIP) analysis of H3K9/14ac and H3K4me3 was conducted using purified CD4(+) T cells, with CD45R(+) B cells as a negative control. Our data revealed that these histone modifications at the VPAC1 promoter did indeed parallel its mRNA levels between T and B lymphocytes, but did not decrease during T cell signaling. Collectively, these data strongly imply a euchromatin nuclear position for the VPAC1 locus irrespective of the activation status of T cells.

Indexed as

Epigenesis, GeneticAcetylationAnimalsBase SequenceCD4-Positive T-LymphocytesCell NucleusChromatin ImmunoprecipitationDNA PrimersDown-RegulationEuchromatinMethylationMicePolymerase Chain ReactionReceptors, Vasoactive Intestinal Polypeptide, Type IRNA, MessengerSignal TransductionDNA PrimersEuchromatinReceptors, Vasoactive Intestinal Polypeptide, Type IRNA, Messenger

Identifiers

PMID19729043
PMCPMC2771554
OpenAlexW1994408529

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.